ArticleJournal of neuro-oncology2026
Multi-fraction stereotactic body radiotherapy for spinal metastases.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSingle-fraction stereotactic body radiotherapy (SBRT) has demonstrated efficacy in the management of spinal metastases. This study sought to investigate the role of multi-fraction spine SBRT in managing metastatic spinal tumors, particularly for tumors large in volume, compressing the spinal cord, or previously irradiated with conventional external beam radiotherapy (EBRT).
methodsOverall, 146 treatments were analyzed from a prospectively maintained spine SBRT database from 2002 to 2024. Treatments were excluded for missing baseline imaging or less than 1 month of follow-up. The most prescribed fractionation schemes were 24 Gy/2 fractions, 24 Gy/3 fractions, and 30 Gy/5 fractions. The median tumor volume was 40 cc (IQR: 18–79). Tumors were previously irradiated with EBRT (108 tumors, 74%), and most had epidural tumor extension (109 tumors, 75%).
resultsThe median follow-up was 9 months (IQR: 2–17). Eighteen (12%) tumors exhibited local tumor progression with local tumor control (LTC) rates of 89%, 84%, and 78% at 6-, 12-, and 24- months following SBRT. Lytic lesions (HR: 8.63, 95%CI: 1.11–67.3, p = 0.040) and tumors spanning > 1 vertebral level (HR: 2.76, 95%CI: 1.02–7.46, p = 0.046) were significantly associated with worsened LTC. Pain improvement or stability was noted for 93%, 89%, and 87% of treated cases at 1-, 3-, and 6-months post-SBRT. The median overall survival (OS) was 13 months with KPS ≤ 80 (HR: 0.41, 95%CI: 0.26–0.64, p < 0.001) and radioresistant primary tumor histology (HR: 0.50, 95%CI: 0.31–0.80, p = 0.004) being associated with worsened OS. The crude vertebral compression fracture development rate was 9%.
conclusionMulti-fraction spine SBRT is safe and effective for large spinal metastatic tumors, including those previously irradiated with EBRT.
Indexed as
Identifiers
42043597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.